Related Experiment Video
Updated: Feb 9, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3
Jutta Gärtner1, Tanuja Chitnis2, Angelo Ghezzi3
1Department of Pediatrics and Adolescent Medicine, German Centre for Multiple Sclerosis in Childhood and Adolescence, University Medical Center Göttingen, Germany.
Background:
Disease activity differs in young patients with multiple sclerosis (MS) compared with the overall adult MS population.
Objective:
The objective of this paper is to evaluate the effect of fingolimod 0.5 mg on disease activity in young adults with MS from three randomized, double-blind Phase 3 trials.
Methods:
Annualized relapse rate (ARR), number of new/newly enlarging T2 lesions (neT2), and no evidence of disease activity (NEDA-3) were estimated in the intent-to-treat population at age 20 (youngest) and 30 (young) and compared to the overall population. Models used included a negative binomial regression (ARR/neT2) and a logistic regression (NEDA), with age at baseline as a continuous covariate.
Results:
ARRs were higher in younger patients (all p < 0.05), and significantly reduced with fingolimod versus placebo or interferon beta-1a (IFN β-1a), with the percentage reduction inversely proportional to age. Fingolimod was significantly associated with a lower number of neT2 lesions versus placebo/IFN in all age groups except versus IFN in the youngest patients. Regardless of age, fingolimod-treated patients were more likely to achieve NEDA-3 versus placebo/IFN β-1a, with strongest benefits in the youngest patients (all p < 0.05).
Conclusions:
Young adults show higher levels of MS disease activity, and may particularly benefit from fingolimod treatment compared with the overall study population.
Insights
Young adults with multiple sclerosis (MS) experience higher disease activity. Fingolimod treatment significantly reduced relapses and new lesions, showing greater benefits in younger patients compared to the general MS population.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Multiple sclerosis (MS) exhibits distinct disease activity patterns in young adults compared to the general adult population.
- Understanding these differences is crucial for effective treatment strategies.
Purpose of the Study:
- To assess the efficacy of fingolimod 0.5 mg in managing disease activity in young adults with MS.
- Evaluate treatment effects across different age strata within the young adult demographic.
Main Methods:
- Analysis of data from three randomized, double-blind Phase 3 trials.
- Comparison of annualized relapse rate (ARR), new/enlarging T2 lesions (neT2), and no evidence of disease activity (NEDA-3) between age groups and treatment arms.
- Statistical modeling using negative binomial and logistic regression, with age as a covariate.
Main Results:
- Younger patients exhibited higher ARR, which was significantly reduced by fingolimod.
- Fingolimod demonstrated a significant reduction in neT2 lesions across most age groups compared to placebo or interferon beta-1a (IFN β-1a).
- Fingolimod treatment led to higher rates of NEDA-3 achievement, with the most pronounced benefits observed in the youngest patients.
Conclusions:
- Young adults with MS present with elevated disease activity.
- Fingolimod treatment offers significant benefits for young adults with MS, potentially exceeding those seen in the overall adult population.
Related Concept Videos
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Phase Transitions: Sublimation and Deposition

